The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TWOU, SRPT, SNDL and MGNX

NEW YORK, Oct. 04, 2019 (GLOBE NEWSWIRE) — NEW YORK, October 4, 2019 – The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.        2U, Inc. (NASDAQGS: TWOU)
Class Period: February 26, 2018 to July 30, 2019
Lead Plaintiff Deadline: October 7, 2019
The lawsuit alleges that throughout the class period, 2U, Inc. made materially false and/or misleading statements and/or failed to disclose that: (a) 2U’s business model was fundamentally flawed because the Company’s costs were growing disproportionately as it grew in size and complexity; (b) 2U could not take advantage of the promised economies of scale because its costs to attract each marginal student were actually increasing, not decreasing, as represented; (c) 2U was facing heightened competitive headwinds as alternative offerings flooded the marketplace and universities developed online courses in-house; (d) 2U’s growth rate in student enrollment was decelerating and was poised to decline as the Company reached market saturation; (e) 2U’s  growth  strategy  was  unsustainable,  as  the  Company  faced accelerating costs and had insufficient capital to achieve positive cash flows, improve margins or continue its revenue growth; and (f) as a result of (a)-(e), above, Defendants lacked any reasonable basis to issue 2U’s projections and financial forecasts.Get additional information about the TWOU lawsuit: http://www.kleinstocklaw.com/pslra-1/2u-inc-loss-submission-form?wire=3 
Sarepta Therapeutics, Inc. (NASDAQ: SRPT)
Class Period: September 6, 2017 to August 19, 2019
Lead Plaintiff Deadline: October 29, 2019
The lawsuit alleges that Sarepta Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) golodirsen, Sarepta’s drug for the treatment of Duchenne muscular dystrophy, posed significant safety risks to patients; (ii) consequently, the New Drug Application package for golodirsen’s accelerated approval was unlikely to receive Food and Drug Administration approval; and (iii) as a result, Sarepta’s public statements were materially false and misleading at all relevant times.Get additional information about the SRPT lawsuit: http://www.kleinstocklaw.com/pslra-1/sarepta-therapeutics-inc-loss-submission-form?wire=3 
Sundial Growers Inc. (NASDAQ: SNDL)
Class Period: pursuant and/or traceable to the registration statement issued in connection with Sundial’s August 1, 2019 initial public stock offering.
Lead Plaintiff Deadline: November 25, 2019
During the class period, Sundial Growers Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Sundial failed to supply saleable cannabis in line with contractual obligations to Zenabis Global Inc.; (2) due to material quality issues, Zenabis had to return or reject a total of 554 kg of cannabis to Sundial, valued at approximately U.S. $1.9 million (C$2.5 million); and (3) as a result, defendants’ statements about Sundial’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.Get additional information about the SNDL lawsuit: http://www.kleinstocklaw.com/pslra-1/sundial-growers-inc-loss-submission-form?wire=3 
MacroGenics, Inc. (NASDAQGS: MGNX)
Class Period: February 6, 2019 to June 3, 2019
Lead Plaintiff Deadline: November 12, 2019
The complaint alleges that during the class period MacroGenics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (a) the Company had conducted the progression-free survival (“PFS”) and first interim overall survival (“OS”) analyses for the SOPHIA trial by no later than October 10, 2018; (b) the October 2018 PFS analysis showed a 0.9 month improvement in PFS; and (c) the October 2018 OS interim analysis did not produce a statistically significant result and the interim OS Kaplan-Meier curves crossed in several spots (thereby violating the constant hazard assumption) and separated late.Get additional information about the MGNX lawsuit: http://www.kleinstocklaw.com/pslra-1/macrogenics-inc-loss-submission-form?wire=3 
Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com 

What are you thoughts on this Stocks information?